Table 1 Baseline characteristics of patients
From: Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis
Parameters | All patients (n = 57) | CHB group (n = 11) | Non-CHB group (n = 46) | p Valuea |
|---|---|---|---|---|
Demographic characteristics | ||||
 Female, n (%) | 43 (75) | 7 (64) | 36 (78) | 0.311 |
 Age, yr | 51 (45–59) | 49 (41–53) | 52 (46–60) | 0.311 |
 Disease duration, mo | 24 (7–102) | 120 (6–120) | 24 (7–72) | 0.345 |
 Smoking, n (%) | 12 (21) | 2 (18) | 10 (22) | 0.795 |
Disease activity indicators | ||||
 TJC28 | 9 (5–16) | 5 (2–9) | 11 (5–16) | 0.021 |
 SJC28 | 6 (3–9) | 5 (2–8) | 6 (4–10) | 0.300 |
 PtGA | 6 (5–8) | 5 (3–6) | 6 (5–8) | 0.007 |
 PrGA | 6 (4–7) | 5 (3–6) | 6 (5–8) | 0.006 |
 Pain VAS | 5 (4–6) | 4 (2–5) | 6 (4–7) | 0.023 |
 CRP, mg/L | 32.0 (14.8–61.0) | 24.9 (15.4–66.8) | 32.6 (14.2–55.6) | 0.656 |
 ESR, mm/h | 68 (45–98) | 63 (37–105) | 70 (49–93) | 0.627 |
 Positive RF, n (%) | 49 (86) | 10 (91) | 39 (85) | 0.599 |
 Positive ACPA, n (%) | 52 (91) | 11 (100) | 41 (89) | 0.252 |
 DAS28-CRP | 5.3 (4.6–6.1) | 4.7 (4.2–5.8) | 5.6 (5.0–6.3) | 0.024 |
 DAS28-ESR | 6.2 (5.4–7.0) | 5.4 (4.7–6.2) | 6.4 (5.6–7.0) | 0.019 |
 SDAI | 31.8 (21.8–42.3) | 22.1 (17.5–34.2) | 33.0 (26.9–43.7) | 0.026 |
 CDAI | 27 (19–39) | 19 (10–27) | 30 (22–41) | 0.009 |
 RAPID3 | 12.7 (8.8–14.8) | 7.1 (5.5–12.4) | 13.1 (10.6–15.1) | 0.001 |
 HAQ-DI | 1.3 (0.6–1.9) | 0.5 (0.1–1.4) | 1.4 (0.9–2.0) | 0.014 |
Liver function | ||||
 AST, U/L | 16 (14–23) | 22 (17–28) | 16 (14–18) | 0.027 |
 ALT, U/L | 15 (11–21) | 19 (14–31) | 15 (11–19) | 0.087 |
Radiographic status | ||||
 Bony erosions, n (%) | 48 (84) | 9 (82) | 39 (85) | 0.809 |
 JSN subscore | 4 (0–17) | 1 (0–11) | 5 (1–18) | 0.331 |
 JE subscore | 7 (2–20) | 2 (1–23) | 9 (2–19) | 0.447 |
 mTSS | 12 (4–34) | 9 (1–34) | 13 (4–35) | 0.352 |
Previous medications, n (%) | ||||
 Treatment-naïveb | 35 (61) | 5 (46) | 30 (65) | 0.226 |
 Glucocorticosteroids | 21 (37) | 4 (36) | 17 (37) | 0.971 |
 Methotrexate | 10 (18) | 3 (27) | 7 (15) | 0.345 |
 Leflunomide | 10 (18) | 0 | 10 (22) | NA |
 Sulfasalazine | 6 (11) | 2 (18) | 4 (9) | 0.357 |
 Hydroxychloroquine | 5 (9) | 3 (27) | 2 (4) | 0.016 |
 Biologic DMARDs | 1 (2) | 0 | 1 (2) | NA |
Initial medications, n (%) | ||||
 Glucocorticosteroids | 44 (77) | 8 (73) | 36 (78) | 0.694 |
 Methotrexate | 54 (95) | 10 (91) | 44 (96) | 0.527 |
 Leflunomide | 39 (68) | 0 | 39 (85) | < 0.001 |
 Sulfasalazine | 10 (18) | 9 (82) | 1 (2) | < 0.001 |
 Hydroxychloroquine | 12 (21) | 10 (91) | 2 (4) | < 0.001 |
 Biologic DMARDs | 25 (44) | 3 (27) | 22 (48) | 0.217 |